Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IP Group PLC Regulatory Filings 2023

Jun 8, 2023

4852_rns_2023-06-08_98f6f1fe-7dc6-4244-94a7-33b007f2d773.html

Regulatory Filings

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 0982C

IP Group PLC

08 June 2023

FOR RELEASE ON 08 June 2023

IP Group - Life Sciences investor update

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, announces that it will hold a life sciences investor update on Thursday June 15 2023 featuring Dr Gordon Sanghera, CEO of Oxford Nanopore Technologies plc, and Professor Sir Peter Donnelly, CEO of portfolio company Genomics.

The event will be hosted by CEO Greg Smith and Dr Sam Williams, Managing Partner of Life Sciences at IP Group, and, as announced on 20 April 2023, will be followed by the Group's Annual General Meeting at 11am. Further details of the event and how to register can be found here: bit.ly/3oUjNqb.

The update will also be available remotely through the Investor Meet Company platform. Questions can be submitted in advance of the event via the Investor Meet Company Platform up to 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: https://www.investormeetcompany.com/ip-group-plc/register-investor. Investors who already follow IP Group plc on the Investor Meet Company platform will automatically be invited.

No material new information will be released by the Company during the presentation.

For more information, please contact:

IP Group plc www.ipgroupplc.com
Liz Vaughan-Adams, Communications +44 (0) 20 7444 0062/+44 (0) 7967 312125
Portland
Vic Wallin

Alex Donaldson
+44 (0) 7973 823119

+44 (0) 7516 729702

Notes for editors

About IP Group

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science investor, we develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

For more information, please visit our website at www.ipgroupplc.com.

ENDS

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUPUBCQUPWUMR